Michael H. Davidson, Chief Executive Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 306,293 shares at $36.13 ($10.6M) on 2026-02-24, disclosed to the SEC on 2026-02-26.
Open-market sale of $10.6M NAMS by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.13 | 61,547 | $2.2M | 21.0% |
| 2 | $36.46 | 3,161 | $115K | 1.1% |
| 3 | $35.11 | 46,517 | $1.6M | 15.4% |
| 4 | $35.96 | 10,436 | $375K | 3.5% |
| 5 | $36.68 | 1,300 | $48K | 0.5% |
| 6 | $33.63 | 165,408 |
| $5.6M |
| 52.6% |
| 7 | $34.44 | 17,924 | $617K | 5.8% |
| Total | $34.53 avg | 306,293 | $10.6M | 100% |
| Filing → |
| NAMS | BUY | 2024-08-22 | $81K | — | Filing → |
| NAMS | BUY | 2024-06-24 | $173K | — | Filing → |
| CLBS | BUY | 2020-09-10 | $100K | — | Filing → |